References
- 1. M. Burnier and H. R. Brunner, Angiotensin II receptor antagonists, Lancet 355 (2000) 637-645; DOI: 10.1016/S0140-6736(99)10365-9.
- 2. G. K. Aulakh, R. K. Sodhi and M. Singh, An update on non-peptide angiotensin receptor antagonists and related RAAS modulators, Life Sci. 81 (2007) 615-639; DOI: 10.1016/j.lfs.2007.06.007.
- 3. P. D. Bari and A. R. Rote, RP-LC and HPTLC methods for the determination of olmesartan medoxomil and hydrochlorothiazide in combined tablet dosage forms, Chromatographia 69 (2009) 1469-1472; DOI: 10.1365/s10337-009-1094-z.
- 4. D. Liu, P. Hu, N. Matsushima, X. Li, L. Li and J. Jiang, Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry, J. Chromatogr. B. 856 (2007) 190-197; DOI: 10.1016/j.jchromb.2007.05.049.
- 5. V. V. Vaidya, M. N. Roy, S. M. Yetal, S. S. Joshi and S. A. Parekh, LC-MS-MS determination of olmesartan in human plasma. Chromatographia 67 (2008) 174-150; DOI: 10.1365/s10337-007-0453-x.
- 6. D. Liu, J. Jiang, P. Wang, S. Feng and P. Hu, Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry, J. Chromatogr. B 878 (2010) 743-748. DOI: 10.1016/j.jchromb.2010. 01.009.
- 7. R. N. Sharma and S. S. Pancholi, RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions, Acta Pharm. 60 (2010) 13-24. DOI: 10.2478/v10007-010-0010-2.
- 8. N. J. Shah, B. N. Suhagia, R. R. Shah and N. M. Patel, Development and validation of a simultaneous HPTLC method for the estimation of olmesartan medoxomil and hydrochlorothiazide in tablet dosage form, Indian J. Pharm. Sci. 69 (2007) 834-836; DOI: 10.4103/0250-474X.58190.
- 9. C. K. Rao, K. K. Kumar, M. V. Srinivasulu, G. Madhusudhan, K. Mukkanti and K. S. Srinivas, Development and validation of stability-indicating LC method for olmesartan medoxamil, Am. J. Anal. Chem. 3 (2012) 153-160; DOI: 10.4236/ajac.2012.32022.
- 10. C. Mustafa and A. Sacide, Development of a CZE method for the determination of olmesartan medoxomil in tablets, Chromatographia 66 (2007) 929-933; DOI: 10.1365/s10337-007-0424-2.
- 11. M. Celebier and S. Altinoz, S. Determination of olmesartan medoxomil in tablets by uv-vis spectrophotometry, Pharmazie 62 (2007) 419-422; DOI: 10.1691/ph.2007.6.6233.
- 12. A. T. Hemke, M. V. Bhure, K. S. Chouhan, K. P. Gupta and S. G. Wadodkar, UV spectrophotometric determination of hydrochlorothiazide and olmesartan medoxomil in pharmaceutical formulation, E-J. Chem. 7 (2010) 1156-1161; DOI: 10.1155/2010/826585.
- 13. S. Caglar and A. Onal, Two simple and rapid spectrophotometric methods for the determination of a new antihypertensive drug olmesartan in tablets, J. Anal. Chem. 65 (2010) 239-243; DOI: 10.1134/S1061934810030056.
- 14. I. A. Darwish, Kinetic spectrophotometric assays for determination of trimetazidine dihydrochloride. Anal. Chim. Acta 551 (2005) 222-231; DOI: 10.1016/j.aca.2005.07.027.
- 15. I. A. Darwish, Analytical study for the charge transfer complexes of losartan potassium, Anal. Chim. Acta 549 (2005) 212-220; DOI: 10.1016/j.aca.2005.06.023.
- 16. I. A. Darwish, H. A. Abdel-Wadood and N. A. Abdel-Latif, Validated spectrophotometric and fluorimetric assays for analysis of clozapine in tablets and urine, Ann. Chim. 95 (2005) 345-356; DOI: 10.1002/adic.200590039.
- 17. A. T. Fidler, E. L. Baker and R. E. Letz, Neurobehavioural effects of occupational exposure to organic solvents among construction painters, Br. J. Ind. Med. 44 (1987) 292-308; DOI: 10.1136/ oem.44.5.292.
- 18. H. Wennborg, J. P. Bonde, M. Stenbeck and J. Olsen, Adverse reproduction outcomes among employees working in biomedical research laboratories, Scand. J. Work Environ. Health 28 (2002) 5-11; DOI: 10.5271/sjweh.640.
- 19. H. F. Askal, Spectrophotometric study of the charge transfer complexes of some pharmaceutical butyrophenones, Talanta 44 (1997) 1749-1755; DOI: 10.1016/S0039-9140(97)00043-X.
- 20. I. A. Darwish, A. M. Mahmoud and A. A. Al-Majed, A novel analytical approach for reducing the consumption of organic solvents in the charge transfer-based spectrophotometric analysis: application in the analysis of certain antihypertensive drugs, Acta Pharm. 60 (2010) 493-501; DOI: 10.2478/v10007-010-0035-6.
- 21. A. Taha and G. Rücker, Utility of pi-acceptors in alkaloid assay, Arch. Pharm. (Weinheim) 310 (1977) 485-494; DOI: 10.1002/ardp.19773100608.
- 22. C. Rosendorff, R. Dubiel, J. Xu and K. J. Chavanu, Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy, Am. J. Cardiol. 104 (2009) 359-365; DOI: 10.1016/j.amjcard.2009.03.042.
- 23. S. G. Chrysant, Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension, Expert Rev. Cardiovasc. Ther. 8 (2009) 887-895; DOI: 10.1586/erc.09.85.
- 24. D. J. Kereiakes, J. M. Neutel, H. A. Punzi, J. Xu, L. J. Lipka and R. Dubiel, Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate, Am. J. Cardiovasc. Drugs 7 (2007) 361-372; DOI: 10.2165/00129784-200707050-00006.
- 25. S. G. Chrysant, M. A. Weber, A. C. Wang and D. J. Hinman, Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide, Am. J. Hypertens. 17 (2004) 252-259; DOI: 10.1016/j.amjhyper.2003.11.003.